February 6, 2014, Neurocrine Biosciences (NASDAQ:NBIX) reported financial results for the fourth quarter and full year ended 2013. The company reported total revenues in the fourth quarter of $0.73 million, dead-on with our expectations. Revenues have been pegged at around $0.7 million for all four quarters in 2013. Research and development expenses were $8.9 million, around $0.6 million below our estimate. General and administrative expenses of $3.3 million came in essentially right in-line with our model. The company reported a loss of $10.6 million ($0.16 per share) for the quarter, roughly $0.01 better than our expectation of ($0.17) on slightly lower R&D.
For the full year 2013, revenues totaled $2.9 million, a sizable drop from the $53.1 million...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|